Noticias y eventos de Atrium Therapeutics Inc (RNA)RNAAtrium Therapeutics Inc

Atrium Therapeutics Doses First Patient in PRKAG2 Trial

Atrium Therapeutics announced that the first patient has been dosed in the Phase 1/2 Corventis clinical trial evaluating ATR 1072, its investigational therapy for the potential treatment of PRKAG2 syndrome. The company expects to report initial proof-of-concept data from Corventis in the second half of 2027.

Atrium Therapeutics Completes $50M Private Placement Financing

Atrium Therapeutics announced that it has entered into a securities purchase agreement with a group of institutional investors for a private placement financing. The private placement is expected to result in aggregate gross proceeds to the company of approximately $50M, before deducting placement agent fees and other offering expenses. The private placement includes participation from Sirenia Capital Management LP, Aberdeen Investments, Montanova, Sessa Capital, Casdin Capital, a life sciences-focused institutional investor and others. Pursuant to the terms of the purchase agreement, the company agreed to issue and sell an aggregate of (i) 5,170,384 shares of its common stock, at a price of $7.93 per share, and (ii) pre-funded warrants to purchase up to 1,134,930 shares of common stock, at a price of $7.929 per pre-funded warrant, which equals the per share price of $7.93 less the exercise price $0.001 for such pre-funded warrant. The pre-funded warrants are immediately exercisable and will expire when exercised in full. The private placement was priced at-the-market under the rules of The Nasdaq Stock Market. The private placement is expected to close on or about October 9. Leerink Partners acted as lead placement agent for the private placement. Cantor, Barclays and Wells Fargo Securities acted as placement agents for the private placement.

Atrium Therapeutics Q2 Revenue at $3M

Reports Q2 revenue $3M vs $3.85M last year. "Our team continues to execute well, achieving FDA clearance of our IND for ATR 1072 and launching Corventis - Atrium's first Phase 1/2 trial and the first clinical study to evaluate a potential disease-modifying treatment for people living with PRKAG2 syndrome," said Kathleen Gallagher, President and Chief Executive Officer of Atrium Therapeutics. "Atrium's precision approach to genetic cardiomyopathies is part of a burgeoning frontier in medicine. Our experienced team is well-positioned to continue advancing and efficiently expanding our pipeline with urgency on behalf of patients and clinicians."